# OnCo record destiny-crc02 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/destiny-crc02/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "destiny-crc02", "NCT04744831" ;
  schema:name "DESTINY-CRC02"@en ;
  schema:description "Enhertu shrank about four in ten heavily pretreated HER2-positive bowel cancers, including ones that had already stopped responding to other HER2 drugs."@en ;
  schema:url <https://onco.cc/trials/destiny-crc02/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04744831> ;
  onco:status "positive" ;
  onco:phase "2" ;
  schema:startDate "2021-03-05" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/her2-amplified-colorectal/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/tumour-agnostic/> ;
  onco:trials <https://onco.cc/trials/destiny-crc01/>, <https://onco.cc/trials/mountaineer-03/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015/>, <https://onco.cc/key-papers/paper-destiny-crc02-lancet-oncol-2024/> .